Cardiol Therapeutics Files 6-K, Confirms 20-F Annual Reporting
Ticker: CRDL · Form: 6-K · Filed: Feb 21, 2024 · CIK: 1702123
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer, compliance
TL;DR
**Cardiol Therapeutics just filed a routine 6-K, confirming they're a foreign private issuer and will file annual reports on Form 20-F.**
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K with the SEC on February 21, 2024, indicating its status as a foreign private issuer. The filing confirms the company will file annual reports under Form 20-F and includes a news release as Exhibit 99.1. This routine filing updates the public record regarding the company's reporting obligations.
Why It Matters
This filing clarifies Cardiol Therapeutics' reporting framework as a foreign private issuer, providing transparency to investors regarding its compliance with SEC regulations.
Risk Assessment
Risk Level: low — This is a routine administrative filing with no material financial or operational disclosures that would impact risk.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — registrant
- SEC (company) — regulatory body
- February 2024 (date) — month of report
- February 21, 2024 (date) — filing date
- 001-40712 (other) — Commission File Number
FAQ
What type of report did Cardiol Therapeutics Inc. file?
Cardiol Therapeutics Inc. filed a Form 6-K, which is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934'.
When was this 6-K filing submitted?
The 6-K filing was submitted on February 21, 2024, and the conformed period of report is also February 2024.
Under which form will Cardiol Therapeutics Inc. file its annual reports?
Cardiol Therapeutics Inc. will file its annual reports under Form 20-F, as indicated by the 'X' mark in the filing.
What is the Commission File Number for Cardiol Therapeutics Inc.?
The Commission File Number for Cardiol Therapeutics Inc. is 001-40712.
What exhibit was included with this 6-K filing?
Exhibit 99.1, described as a 'News Release date', was included with this 6-K filing.
Filing Stats: 223 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2024-02-21 07:29:27
Filing Documents
- form6k.htm (6-K) — 6KB
- exhibit99-1.htm (EX-99.1) — 11KB
- exhibit99-1xu001.jpg (GRAPHIC) — 8KB
- 0001062993-24-003785.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: February 21, 2024 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer